AARD Clinical trials

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Published August 12, 2025 at 12:00 PM

SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in the validated diet-induced obesity (DIO) mouse model (a conventional model recognized for its strong translational relevance in the field of glucagon-like peptide-1 receptor agonists (GLP-1RAs)) demonstrated potential applications for ARD-201, including for the attenuation of weight gain after withdrawal from GLP-1RA therapies, as a monotherapy for weight loss without GLP-1RA therapy, as well as for weight loss in combination with GLP-1RA therapy. Details of the study will be submitted for peer review publication.

Related Questions

What potential market size and revenue opportunity could ARD-201 represent if it reaches commercialization? Will the combination data with GLP‑1RAs create a competitive advantage or partnership opportunities with existing GLP‑1RA manufacturers? How credible is the DIO mouse model data in predicting human efficacy for obesity treatment? What are the risks that the preclinical efficacy may not translate into clinical success, and how might that impact the stock? Could the announced data trigger any new licensing or partnership discussions that might affect the company’s valuation? How might the anticipated peer‑review publication influence analyst coverage and investor sentiment? What are the potential regulatory pathways and milestones for ARD-201, and how could they impact future share performance? How will the preclinical results for ARD-201 affect Aardvark Therapeutics' stock price in the short term? What is the expected timeline to move from preclinical data to human clinical trials for ARD-201? How does ARD-201’s mechanism of action compare to existing GLP‑1R agonists and other obesity therapeutics in development?